Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Amyloidosis × birtamimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 3 Paraproteinemias 1 Amyloidosis 1 Alzheimer Disease 1

Interventions

Dexamethasone 5 Cyclophosphamide 4 Bortezomib 4 Melphalan 3 Lenalidomide 2 Doxycycline 2 Calcium Dobesilate 2 ixazomib 1 daratumumab 1 birtamimab 1 belantamab mafodotin 1 Vinorelbine 1 Thalidomide 1 Gemcitabine 1 Etoposide 1 Etanercept 1 Doxorubicin 1 Cisplatin 1 Antineoplastic Protocols 1 ARQ 197 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02632786 2019-04-05

PRONTO

Prothena Biosciences Ltd.

Phase 2 Completed

129 enrolled 18 charts

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡